Business Daily from THE HINDU group of publicationsSaturday, Feb 24, 2007
New Delhi, Feb. 23
Ranbaxy Laboratories will appeal against the ruling of the US District Court of New Jersey in favour of Japanese company, Astellas Pharma Inc. on its generic version of Flomax prostate drug. "We will appeal against the ruling in the Court of Appeals for the Federal Circuit," said a Ranbaxy spokesperson. On Friday, Japan's Astellas had said that it had won its suit filed to prevent Ranbaxy from releasing an early generic version of its Flomax prostate drug. The case had been filed jointly by Astellas and Germany's Boehringer Ingelheim, its US marketing partners for the drug. The drug is prescribed in the treatment of enlarged prostates, and its patent expires in October 2009
Ranbaxy Laboratories will appeal against the ruling of the US District Court of New Jersey in favour of Japanese company, Astellas Pharma Inc. on its generic version of Flomax prostate drug. "We will appeal against the ruling in the Court of Appeals for the Federal Circuit," said a Ranbaxy spokesperson. On Friday, Japan's Astellas had said that it had won its suit filed to prevent Ranbaxy from releasing an early generic version of its Flomax prostate drug. The case had been filed jointly by Astellas and Germany's Boehringer Ingelheim, its US marketing partners for the drug. The drug is prescribed in the treatment of enlarged prostates, and its patent expires in October 2009
http://www.blonnet.com/2007/02/24/stories/2007022404200200.htm
For any querry:-
09896868668
deepakmiglani@hotmail.com
No comments:
Post a Comment